grant
Process development for manufacturing eCD4-Ig
NIHUS FederalResearch GrantFY2025AIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAffinity ChromatographyAnionsAntibodiesApplications GrantsAssayBindingBioassayBiologicalBiological AssayBuffersCell BodyCell LineCellLineCellsChromatographyCirculationClinicClinical Treatment MoabCustomDNA mutationDevelopmentDrugsELISAEarly-Stage Clinical TrialsEnzyme-Linked Immunosorbent AssayExclusionFcRnFcRn neonatal transfer proteinFormulationFundingGenetic ChangeGenetic defectGenetic mutationGlycoengineeringGrantGrant ProposalsHIVHIV Envelope Glycoprotein gp120HIV Envelope Protein gp120HIV InfectionsHIV ReceptorsHIV env Protein gp120HTLV-III InfectionsHTLV-III ReceptorsHTLV-III gp120HTLV-III-LAV InfectionsHalf-LifeHuman Immunodeficiency VirusesHuman T-Lymphotropic Virus Type III InfectionsHydrophobic InteractionsImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologicsInjectableIntravenousLAV-HTLV-IIILength of LifeLife ExtensionLongevityLymphadenopathy-Associated VirusMarketingMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMeasuresMedicationMolecular InteractionMonoclonal AntibodiesMutationOralOutsourcingPatientsPerfusionPharmaceutical PreparationsPhasePhase 1 Clinical TrialsPhase I Clinical TrialsProcessProductionProteinsProteolytic ClippingProteolytic ProcessingReceptor ProteinRegimenResistanceSIVSimian Immunodeficiency VirusesSiteStrains Cell LinesSubcutaneous InjectionsSulfateSynthetic antigen binderTechnology TransferTemperatureTherapeuticTimeValidationVirus-HIVViscosityWorkaffinity purificationanalytical methodantibody mimeticsantibody-like binderantibody-like moleculeantibody-like proteinantibody-like reagentbiologiccultured cell linecustomsdevelopmentaldrug/agentenzyme linked immunoassayfabrication technologygenome mutationgp120gp120 ENV Glycoproteingp120(HIV)improvedintravenous administrationintravenous injectionmAbsmanufacturemanufacturing process developmentmanufacturing qualitymanufacturing technologymimeticsmonoclonal Absnative protein drugneonatal Fc receptorpharmaceutical proteinphase I protocolpillpreventpreventingprocess optimizationprotein drug agentprotein-based drugreceptorresistantsialylationsmall moleculesmall molecule therapeuticssubcutaneoussubdermalsubdermal injectionsulfotyrosinesynthetic antigen binding reagenttherapeutic proteintyrosine O-sulfatetyrosine sulfatevalidations
Description preview
ABSTRACT
eCD4-Ig is an antibody-like therapeutic for HIV that was constructed by fusing CD4 domains 1 and 2, and
an HIV coreceptor-mimetic sulfopeptide, to the N- and C-termini of the constant Fc region of an antibody.
eCD4-Ig will join an emerging class of long-acting therapeutics for treating and preventing HIV infection. As
a consequence of…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click